Hosted on MSN
A math notebook or an art gallery?
A math notebook or an art gallery? 🎨📖!! Met Office issues thunderstorm and rain forecast for Wednesday and Thursday What punishment could Argentina face for Falklands banner? Wife of passenger ...
After rolling out to Google AI subscribers earlier this month, the Gemini app has now launched notebooks to free users. On gemini.google.com, you’ll find a new “Notebooks” section in the side panel ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company has been pushing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months. December brought an FDA thumbs up for its new motion sickness drug Nereus. Then in January, the U.S. regulator ...
LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global ...
Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and ...
The FDA's usual end-of-year flurry of regulatory approvals is a little lighter than usual, but the agency has delivered some end-of-year cheer to Vanda Pharma after giving the go-ahead to its drug for ...
Dec 30 (Reuters) - Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the ...
The company filed a FDA application for its psoriasis drug Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check. The company announced last week it filed a ...
WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...
Vanda Pharmaceuticals shares rose after the company said it had submitted a biologics license application to the Food and Drug Administration for its generalized pustular psoriasis treatment. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results